medigraphic.com
ISSN 1561-3119 (Electronic)

2020, Number 3

<< Back Next >>

Rev Cubana Pediatr 2020; 92 (3)

Clinical epidemiological characterization of children visceral leishmaniasis

Piña BCE, Fernández FML, Piña RLK

Language: Spanish
References: 28
Page: 1-16
PDF size: 443.99 Kb.


ABSTRACT

Introduction: Visceral leishmaniasis is the most severe clinical form of leishmaniasis that mainly affects children and is potentially fatal.
Objective: To explain the clinical-epidemiological characterization of visceral leishmaniasis in the pediatric population and its therapeutic response.
Methods: It was conducted a retrospective, longitudinal and descriptive study in the Italian Hospital, Djibouti City in the period from September 2016 to August 2017. The sample group was formed by 166 children under 15 years old that were admitted with a diagnosis of prolonged fever without localization focus and the sample was of 22 children with confirmed diagnosis of visceral leishmaniasis. The information was obtained from the clinical records. Twenty variables were operationalized: sociodemographic, clinical, analytical, therapeutic and evolutive ones. Epidat 3.1 proccessor was used. The results were expressed in absolute values and percentages.
Results: Visceral leishmaniasis was diagnosed in 13.2% children that were admitted in hospital due to prolonged fever, 90.9% of them were from rural areas and 59.1% were undernourished. 77,3% of the cases had antimonial treatment, 90.9% had hospital stay for more than 21 days and the 36.4% had complications due to pneumonia.
Conclusions: Visceral leishmaniasis is a relatively frequent entity in children admitted in the Italian Hospital due to prolonged fever with a predominance of undernourished males, older that five years and from rural areas. Fever and splenomegaly are constant clinical manifestations, and anemia and leucopenia are the main laboratory findings. The use of antimonials is the election treatment with long hospital stay, and pneumonia is the most frequent complication.


REFERENCES

  1. Moreno M, Ortega-Moreno ME, Belizario D, Galindo W, Zerpa O. Epidemiología de la Leishmaniasis Visceral en el estado Nueva Esparta, Venezuela. Período 1995-2015. Dermatol Venez 2016; 54 (1):17-23.

  2. Ready P. Epidemiology of visceral leishmaniasis. Clin Epidemiol. 2014; 6:147.

  3. Tovar C, Yasnot M. Leishmaniasis visceral en América Latina y perspectivas terapéuticas. Rev MVZ Córdoba. 2017;22(Supl):6075-88.

  4. Organización Mundial de la Salud. Leishmaniasis. Nota descriptiva No. 375 Febrero. Ginebra: OMS; 2015 [acceso 11/05/2016]. Disponible en: http://www.who.int/mediacentre/factsheets/fs375/es/

  5. Pan American Health Organization. Leishmaniases. Epidemiological Report of the Americas. Report Leishmaniases No 2. June. Washington. D. C.: PAHO; 2014 [acceso 17/06/2018]. Disponible en: http://new.paho.org/leishmaniasis

  6. Organización Panamericana de la Salud; Organización Mundial de la Salud. Leishmaniasis: Informe Epidemiológico de las Américas. Washington. D. C.: OPS/OMS; 2015 [acceso 13/05/2016]. Disponible en: http://www.paho.org/hq/index.php?option=com_topics&view=article&id=29&Itemid=40754&lang=es

  7. Cordenonzi L, Rezende I, Cardoso PN, Baldaçara LR, Nascimento P, Rodrigo L, Machado MR, et al. HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil. Rev Soc Bras Med Trop. 2014;47(1):38-46.

  8. Word Health Organization WHO Multicentre Growth Reference Study Group. WHO Child Growth Standart: Lenght/height-for-age, weight-for-height and body mass index-for-age: Methods and development. (312 pages). Geneva: WHO; 2006.

  9. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH- 2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-31.

  10. Escosa L, Baquero F, Méndez A. Fiebre de origen desconocido. Pediatr Integr. 2014; 18(1):15-21.

  11. Reyes KL, Quiroz MA, Reyes U, Sánchez-Chávez NP, Reyes-Hernández DP, Hernández-Lira S. Síndrome Febril en el Niño Viajero. Bol Clin Hosp Infant Edo Son. 2015; 32(2); 102-6.

  12. Galé I, Gómez O, Aldana A, Odriozola M, Bouthelier M, de Juan F. Leishmaniasis visceral, nuestra experiencia en 30 años. Rev Esp Pediatr. 2013; 69(2):85-8.

  13. Organización Panamericana de la Salud. Leishmaniasis: productos científicos y técnicos de la OPS/OMS. Informes técnicos. Washington, D.C.: OPS; 2013 [acceso 01/08/2016]. Disponible en: http://www.paho.org/hq/index.php?option=com_topics&view=readall&cid=6018&Itemid=40754 ang=es

  14. Grill F, Zurmendi M. Leishmaniasis visceral en Uruguay. Arch Pediatr Urug. 2017 [acceso 01/07/2018];88(1):32-8. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S168812492017000100007&lng=es

  15. Dias R, Leal R, Fontes T, Yukio M, de Oliveira H, de Queiroz AJ. Visceral Leishmaniasis hospitalizations and seasonality in Fortaleza, Ceará, Northeast Brazil between 2003-2012. Health Biol Sci. 2018; 6(2):128-32.

  16. Pérez F, Montilla M, Muñoz F. Brote de Leishmaniasis en la Comunidad Autónoma de Madrid. Importancia de las medidas de prevención. Enfermer Global. 2016;41:361-74.

  17. Zambrano CP, Ayala MS, Fuya OP, Barraza OC, Rodríguez G. Cartagena: nuevo foco de leishmaniasis visceral urbana en Colombia. Rev Ciencia Desarrollo. 2016;7(1):83-91.

  18. Zambrano CP, Ayala MS, Fuya OP, Montenegro CA, Aya NM, Aguilera-Jaramillo G, et al. Brote urbano de leishmaniasis visceral en Neiva, Colombia. Rev. Salud Pública. 2015;17(4): 514-27.

  19. Apodaca S, Araya S, Martínez C, Lovera D, Arbo A. Comportamiento Clínico de la Leihsmaniosis Visceral en Población Infantil. Diez Años de Experiencia de un Centro de Referencia del Paraguay. Rev Inst Med Trop. 2015;10(1):12-8.

  20. Apodaca S, Araya S, Lovera D, Delgado V, Sanabria G, Arbo A. Leishmaniasis visceral en Niños Inmunocompetentes. Rev Inst Med Trop. 2014;9(1):1-9.

  21. Tovar C, Yasnot M. Leishmaniasis visceral en América Latina y perspectivas terapéuticas. Rev. MVZ Córdoba. 2017;22(Supl):6075-88.

  22. Morizot G, Jouffroy R, Faye A, Chabert P, Belhouari K, Calin R, et al. Antimony to Cure Visceral Leishmaniasis Un responsive to Liposomal Amphotericin B. PLoS Negl Trop Dis. 2016;10 (1):1-7.

  23. de Guglielmo Z, Rodríguez N, Oviedo H. Tratamientos para la Leishmaniasis. Rev Facultad Med. 2018;41(1):4-26.

  24. Portafolio de la Drugs for Neglected Diseases initiative (DNDi). Proyecto colaborativo New VL treatments. Asia: DNDi; 2015 [acceso 19/05/2016]. Disponible en: http://www.dndi.org/diseases-projects/portfolio/new-vl-treatments-asia/

  25. Don B, Ioset JR. Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology. 2014;141(1):140-6.

  26. Ahmed MA, Ahmed AA, Saeed OM, Gamal AK, Tajeldin AM. Epidemiology of visceral leishmaniasis among children in Gadarif hospital, Eastern Sudan. BMC Public Health. 2016;16:1234.

  27. Blázquez-Gamero D, Domínguez-Pinilla N, Chicharro C, Negreira S, Galán P, Pérez-Gorricho B, et al. Hemophagocytic lymphohistiocytosis in children with visceral leishmaniasis. Pediatric Infectious Dis J. 2015;34(6):667-9.

  28. Díaz Díaz T, Sanz de Miguel MP, Caballero Pérez V, García Torralba L, Martín Ruiz N, Castaño Vicente-Gella C. Leishmaniasis visceral en pediatría. Revisión de nuestra casuística. Rev Atalaya Méd. 2015;7:40-4.




2020     |     www.medigraphic.com